Physician profile
David L Snow
NPI 1821096041
$605,365.30
in general payments reported to CMS, 2019-2025
34 companies · $45K in 2025
The $45K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $85K · 2021: $65K · 2022: $92K · 2023: $135K · 2024: $66K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $182K · Consulting Fee: $41K · Travel and Lodging: $14K · Food and Beverage: $7,387 · Honoraria: $1,575 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $181,853.50 |
| Consulting Fee | $41,207.50 |
| Travel and Lodging | $14,162.69 |
| Food and Beverage | $7,386.71 |
| Honoraria | $1,575.00 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205,287.40 | 2020-2025 | Caplyta |
| Allergan, INC. | $139,343.55 | 2019-2021 | |
| Abbvie INC. | $66,238.97 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $51,133.65 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $49,183.98 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $44,478.77 | 2019-2024 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $28,593.96 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $11,122.45 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $2,726.24 | 2020-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $1,319.64 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,196.50 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lundbeck LLC | $958.03 | 2019-2025 | Rexulti |
| Alkermes, INC. | $508.71 | 2021-2025 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $473.85 | 2019-2022 | |
| Bausch Health US, LLC | $455.43 | 2019-2024 | Aplenzin, Wellbutrin |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $448.30 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $405.48 | 2020-2025 | Spravato |
| Eisai INC. | $255.66 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $216.09 | 2020-2022 | |
| Tris Pharma INC | $182.04 | 2022-2025 | Dyanavel Xr |
| Corium, LLC | $165.62 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $129.55 | 2019-2023 | Belsomra |
| Arbor Pharmaceuticals, INC. | $116.51 | 2019-2021 | |
| Shire North American Group INC | $110.37 | 2019 | |
| Neuronetics, INC. | $57.43 | 2019-2020 | |
| Almatica Pharma LLC | $51.92 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Neos Therapeutics, LP | $37.76 | 2019-2025 | Exxua |
| E.R. Squibb & Sons, L.L.C. | $33.56 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $32.79 | 2022-2023 | Quviviq |
| Sage Therapeutics, LLC | $32.00 | 2025 | Zurzuvae |
| Adlon Therapeutics L.P. | $25.61 | 2019-2020 | |
| Pernix Therapeutics Holdings, INC. | $15.49 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.89 | 2020 | |
| Noven Therapeutics, LLC | $13.10 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.